Core Points - The article emphasizes the importance of early screening and standardized clinical diagnosis for lung cancer, which is the most prevalent and deadly malignant tumor in China [1] - It highlights the typical symptoms of early-stage lung cancer and identifies high-risk groups [2] Group 1: Lung Cancer Overview - Lung cancer originates from bronchial mucosa or glands and is mainly classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), with NSCLC being more common and having a relatively better prognosis [1] - Early-stage lung cancer often presents with subtle symptoms, making it difficult to detect [1] Group 2: Symptoms and Detection - Typical symptoms of lung cancer include persistent cough, sputum production, blood-streaked sputum, and dry cough without phlegm, which may not respond to common cough medications [1] - Atypical symptoms such as hoarseness, back pain, or leg pain may indicate lung cancer with bone metastasis, particularly in cases of small cell lung cancer [1] Group 3: High-Risk Groups - Individuals aged 50 to 80 years are considered high-risk for lung cancer, with smoking history being a significant risk factor, particularly for those with a smoking history of 20 pack-years [2] - Other risk factors include pre-existing lung conditions like chronic obstructive pulmonary disease (COPD) or tuberculosis, exposure to secondhand smoke, and occupational hazards involving asbestos, dust, and metal particles [2] - Family history of lung cancer also increases the likelihood of developing the disease [2]

Core Insights - The article highlights the significant achievements of China in the field of new drug development, attributing these successes to the 2015 reform of the drug review and approval system, which has integrated China's clinical research into global multi-center studies [1] - The 2025 European Society for Medical Oncology (ESMO) conference showcased numerous Chinese experts and their research, indicating a growing international collaboration and interest in Chinese innovative pharmaceuticals [1] - The 2025 Sino-European Academic Forum on Thoracic Diseases emphasizes the importance of cross-cultural collaboration and the sharing of clinical practices and innovations between China and Europe [2] Group 1: Drug Development and Innovation - The 2015 drug policy reform has been pivotal in enhancing China's capabilities in clinical research and drug development, leading to significant advancements in treatment options for various diseases [1] - Chinese innovative pharmaceutical companies are increasingly engaging in international licensing collaborations, with high-quality data disclosure being a critical foundation for these partnerships [1] Group 2: Academic Forum Highlights - The 2025 Sino-European Academic Forum focuses on three main themes: local innovation and clinical practice, global advancements and technological breakthroughs, and cross-cultural collaboration in future medicine [2] - Prominent Chinese scholars presented on topics such as vascular disease treatment strategies and precision lung cancer therapy, showcasing China's achievements in clinical practice and research translation [2] Group 3: Clinical Practices and Technologies - The forum included discussions on the differences in lung cancer early screening practices between China and European countries, highlighting China's proactive approach in early diagnosis [5] - The use of surgical robots in thoracic surgery was emphasized as a means to enhance precision and reduce complications, with potential for remote medical applications and AI-driven surgical procedures in the future [6] - The integration of traditional Chinese medicine with modern oncology practices was explored, focusing on improving patient quality of life and addressing adverse reactions to targeted therapies [6]